Alan John Camm

Alan John Camm

Auto-generated profile, based on publicly available information

Alan John Camm

Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, City St. George’s University of London , Cranmer Terrace, London SW17 0RE

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2010 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EAEuropean Heart Rhythm Association
European Heart Rhythm Association
ESEuropean Association for Cardio-Thoracic Surgery
European Association for Cardio-Thoracic Surgery
ACA John Camm
A John Camm
PKPaulus Kirchhof
Paulus Kirchhof
GLGregory Y H Lip
Gregory Y H Lip
FRFrans H Rutten
Frans H Rutten
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

24 August 2012 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ACA. John Camm
A. John Camm
GLGregory Y.H. Lip
Gregory Y.H. Lip
RCRaffaele De Caterina
Raffaele De Caterina
ISIrene Savelieva
Irene Savelieva
DADan Atar
Dan Atar
FVFreek W.A. Verheugt
Freek W.A. Verheugt
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

1 October 2010 in EP Europace
Verified
Journal Article
Open access
PDF file
D(Developed with the special contribution of the European Heart Rhythm Association (EHRA)
Developed with the special contribution of the European Heart Rhythm Association (EHRA)
E(Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)
Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)
ACA. John Camm
A. John Camm
PKPaulus Kirchhof
Paulus Kirchhof
GLGregory Y.H. Lip
Gregory Y.H. Lip
IZIgor Zupan
Igor Zupan
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

24 August 2012 in EP Europace
Verified
Journal Article
Open access
PDF file
ACA. John Camm
A. John Camm
GLGregory Y.H. Lip
Gregory Y.H. Lip
RCRaffaele De Caterina
Raffaele De Caterina
ISIrene Savelieva
Irene Savelieva
DADan Atar
Dan Atar
FVFreek W.A. Verheugt
Freek W.A. Verheugt
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

1 September 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ACA. John Camm
A. John Camm
PAPierre Amarenco
Pierre Amarenco
SHSylvia Haas
Sylvia Haas
SHSusanne Hess
Susanne Hess
PKPaulus Kirchhof
Paulus Kirchhof
ATAlexander G.G. Turpie
Alexander G.G. Turpie
Although non-vitamin K antagonist oral anticoagulants are recommended for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial results, there is a need for safety and efficacy data from unselected patients in everyday clinical practice. XANTUS investigated the safety and efficacy of the Factor Xa inhibitor rivaroxaban in routine clinical use in the NVAF setting. Consecutive consenting patients with NVAF newly started on rivaroxaban were eligible and were followed up at ∼3-month intervals for 1 year, or for at least 30 days after permanent discontinuation. All adverse events (AEs) were recorded as AEs or serious AEs; major outcomes (including major bleeding, symptomatic thromboembolic events [stroke, systemic embolism, transient ischaemic attack, and myocardial infarction], and all-cause death) were centrally adjudicated. There were 6784 patients treated with rivaroxaban at 311 centres in Europe, Israel, and Canada. Mean patient age was 71.5 years (range 19–99), 41% were female, and 9.4% had documented severe or moderate renal impairment (creatinine clearance <50 mL/min). The mean CHADS2 and CHA2DS2-VASc scores were 2.0 and 3.4, respectively; 859 (12.7%) patients had a CHA2DS2-VASc score of 0 or 1. The mean treatment duration was 329 days. Treatment-emergent major bleeding occurred in 128 patients (2.1 events per 100 patient-years), 118 (1.9 events per 100 patient-years) died, and 43 (0.7 events per 100 patient-years) suffered a stroke. XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice. Clinicaltrials.gov: NCT01606995.

16 February 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SNStanley Nattel
Stanley Nattel
EGEduard Guasch
Eduard Guasch
ISIrina Savelieva
Irina Savelieva
FCFrancisco G. Cosio
Francisco G. Cosio
IVIrene Valverde
Irene Valverde
ACA. John Camm
A. John Camm
Atrial fibrillation (AF) is generally considered a progressive disease, typically evolving from paroxysmal through persistent to ‘permanent’ forms, a process attributed to electrical and structural remodelling related to both the underlying disease and AF itself. Medical treatment has yet to demonstrate clinical efficacy in preventing progression. Large clinical trials performed to date have failed to show benefit of rhythm control compared with rate control, but these trials primarily included patients at late stages in the disease process. One possible explanation is that intervention at only an early stage of progression may improve prognosis. Evolving observations about the progressive nature of AF, along with the occurrences of major complications such as strokes upon AF presentation, led to the notion that earlier and more active approaches to AF detection, rhythm-reversion, and maintenance of sinus rhythm may be a useful strategy in AF management. Approaches to early and sustained rhythm control include measures that prevent development of the AF substrate, earlier catheter ablation, and novel antiarrhythmic drugs. Improved classifications of AF mechanism, pathogenesis, and remodelling may be helpful to enable patient-specific pathophysiological diagnosis and therapy. Potential novel therapeutic options under development include microRNA-modulation, heatshock protein inducers, agents that influence Ca2+ handling, vagal stimulators, and more aggressive mechanism-based ablation strategies. In this review, of research into the basis and management of AF in acute and early settings, it is proposed that progression from paroxysmal to persistent AF can be interrupted, with potentially favourable prognostic impact.